Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Kaohsiung J Med Sci ; 36(11): 885-894, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32643867

RESUMEN

The dysregulation of miR-532-5p is involved in the development of several cancers. Nevertheless, the roles of miR-532-5p in osteosarcoma (OS) have yet to be illuminated. In the present study, we found that miR-532-5p was significantly downregulated in both OS tissues and cell lines. The low level of miR-532-5p was associated with advance clinical stage and poor overall survival in patient with OS. The functional experiments implied that upregulation of miR-532-5p restrained OS U2OS cell growth and metastatic ability in vitro; induced apoptosis, and impaired OS cell growth in vivo. Mechanistically, chemokine (C-X-C Motif) ligand 2 (CXCL2) was proved as a target gene of miR-532-5p. The inhibitory effects of miR-532-5p on OS cell were rescued by CXCL2 overexpression. Altogether, we demonstrated that miR-532-5p exerted tumor-inhibitory functions in OS cell via regulating CXCL2.


Asunto(s)
Neoplasias Óseas/genética , Quimiocina CXCL2/genética , MicroARNs/genética , Osteosarcoma/genética , Adolescente , Adulto , Antagomirs/genética , Antagomirs/metabolismo , Apoptosis/genética , Emparejamiento Base , Secuencia de Bases , Neoplasias Óseas/diagnóstico , Neoplasias Óseas/metabolismo , Neoplasias Óseas/mortalidad , Huesos/metabolismo , Huesos/patología , Línea Celular Tumoral , Proliferación Celular , Quimiocina CXCL2/agonistas , Quimiocina CXCL2/metabolismo , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Metástasis Linfática , Masculino , MicroARNs/agonistas , MicroARNs/antagonistas & inhibidores , MicroARNs/metabolismo , Persona de Mediana Edad , Estadificación de Neoplasias , Oligorribonucleótidos/genética , Oligorribonucleótidos/metabolismo , Osteosarcoma/diagnóstico , Osteosarcoma/metabolismo , Osteosarcoma/mortalidad , Fenotipo , Plásmidos/química , Plásmidos/metabolismo , Pronóstico , Transducción de Señal , Análisis de Supervivencia
2.
Basic Clin Pharmacol Toxicol ; 119(6): 540-547, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27194111

RESUMEN

The compound 5-fluorouracil (5-FU) is used in cancer chemotherapy and is known to cause diarrhoea. We recently reported that chemokine (C-X-C motif) ligand 1 (CXCL1) and neutrophils in the colonic mucosa were markedly increased by the administration of 5-FU in mice. Curcumin has anti-inflammatory, antitumour and antioxidant properties. Therefore, we examined the effect of curcumin on 5-FU-induced diarrhoea development and CXCL1 and CXCL2 up-regulation in the colon. Mice were given 5-FU (50 mg/kg, i.p.) daily for 4 days. Curcumin (100 or 300 mg/kg, p.o.) was administered on the day before the first administration of 5-FU and administered 30 min. before the administration of 5-FU. Gene expression levels of CXCL1 and CXCL2 in the colon were examined by real-time RT-PCR. Curcumin reduced the 5-FU-induced diarrhoea development. Under this condition, the CXCL1 and CXCL2 gene up-regulated by 5-FU administration was inhibited by curcumin. The gene expression of CXCL1 and CXCL2 was also enhanced by 5-FU application in vitro. The 5-FU-induced up-regulated CXCL1 and CXCL2 gene expressions were inhibited by curcumin, Bay-117082 and bortezomib, nuclear factor kappa B (NF-κB) inhibitors, C646, a p300/cyclic adenosine monophosphate response element-binding protein-histone acetyltransferase (HAT) inhibitor. In conclusion, these findings suggested that curcumin prevented the development of diarrhoea by inhibiting NF-κB and HAT activation.


Asunto(s)
Antimetabolitos Antineoplásicos/efectos adversos , Antioxidantes/uso terapéutico , Colon Descendente/efectos de los fármacos , Curcumina/uso terapéutico , Diarrea/prevención & control , Suplementos Dietéticos , Fluorouracilo/efectos adversos , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacología , Antiinflamatorios no Esteroideos/uso terapéutico , Antimetabolitos Antineoplásicos/química , Antimetabolitos Antineoplásicos/farmacología , Antioxidantes/administración & dosificación , Antioxidantes/farmacología , Quimiocina CXCL1/agonistas , Quimiocina CXCL1/antagonistas & inhibidores , Quimiocina CXCL1/genética , Quimiocina CXCL1/metabolismo , Quimiocina CXCL2/agonistas , Quimiocina CXCL2/antagonistas & inhibidores , Quimiocina CXCL2/genética , Quimiocina CXCL2/metabolismo , Colon Descendente/inmunología , Colon Descendente/metabolismo , Colon Descendente/fisiopatología , Curcumina/administración & dosificación , Curcumina/farmacología , Diarrea/inducido químicamente , Diarrea/metabolismo , Diarrea/fisiopatología , Proteína p300 Asociada a E1A/agonistas , Proteína p300 Asociada a E1A/antagonistas & inhibidores , Proteína p300 Asociada a E1A/metabolismo , Inhibidores Enzimáticos/farmacología , Fluorouracilo/antagonistas & inhibidores , Fluorouracilo/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/inmunología , Mucosa Intestinal/metabolismo , Mucosa Intestinal/fisiopatología , Masculino , Ratones Endogámicos C57BL , FN-kappa B/agonistas , FN-kappa B/antagonistas & inhibidores , FN-kappa B/metabolismo , Índice de Severidad de la Enfermedad , Técnicas de Cultivo de Tejidos
3.
Toxicon ; 112: 51-8, 2016 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-26844922

RESUMEN

We had previously shown that microcystin-LR (MCLR) could induce lung and liver inflammation after acute exposure. The biological outcomes following prolonged exposure to MCLR, although more frequent, are still poorly understood. Thus, we aimed to verify whether repeated doses of MCLR could damage lung and liver and evaluate the dose-dependence of the results. Male Swiss mice received 10 intraperitoneal injections (i.p.) of distilled water (60 µL, CTRL) or different doses of MCLR (5 µg/kg, TOX5), 10 µg/kg (TOX10), 15 µg/kg (TOX15) and 20 µg/kg (TOX20) every other day. On the tenth injection respiratory mechanics (lung resistive and viscoelastic/inhomogeneous pressures, static elastance, and viscoelastic component of elastance) was measured. Lungs and liver were prepared for histology (morphometry and cellularity) and inflammatory mediators (KC and MIP-2) determination. All mechanical parameters and alveolar collapse were significantly higher in TOX5, 10, 15 and 20 than CTRL, but did not differ among them. Lung inflammatory cell content increased dose-dependently in all TOX groups in relation to CTRL, being TOX20 the largest. The production of KC was increased in lung and liver homogenates. MIP-2 increased in the liver of all TOX groups, but in lung homogenates it was significantly higher only in TOX20 group. All TOX mice livers showed steatosis, necrosis, inflammatory foci and a high degree of binucleated hepatocytes. In conclusion, sub-chronic exposure to MCLR damaged lung and liver in all doses, with a more important lung inflammation in TOX20 group.


Asunto(s)
Toxinas Bacterianas/toxicidad , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Hígado/efectos de los fármacos , Pulmón/efectos de los fármacos , Toxinas Marinas/toxicidad , Microcistinas/toxicidad , Neumonía/inducido químicamente , Animales , Toxinas Bacterianas/administración & dosificación , Toxinas Bacterianas/aislamiento & purificación , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Enfermedad Hepática Inducida por Sustancias y Drogas/fisiopatología , Quimiocina CXCL2/agonistas , Quimiocina CXCL2/metabolismo , Quimiocinas/agonistas , Quimiocinas/metabolismo , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/aislamiento & purificación , Inhibidores Enzimáticos/toxicidad , Hepatitis/etiología , Inyecciones Intraperitoneales , Hígado/inmunología , Hígado/metabolismo , Hígado/patología , Pulmón/inmunología , Pulmón/metabolismo , Pulmón/patología , Masculino , Toxinas Marinas/administración & dosificación , Toxinas Marinas/aislamiento & purificación , Ratones , Microcistinas/administración & dosificación , Microcistinas/aislamiento & purificación , Microcystis/química , Tamaño de los Órganos/efectos de los fármacos , Fosfoproteínas Fosfatasas/antagonistas & inhibidores , Neumonía/metabolismo , Neumonía/patología , Distribución Aleatoria , Pruebas de Toxicidad Subcrónica
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...